Palonosetron "preferred" 5-HT3 antagonist for emesis prevention in oncology patients receiving highly emetogenic chometherapy
Lugano, Switzerland (ots) - A new release of the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology on Antiemesis recommends palonosetron as the "preferred" 5-HT3 antagonist in combination with aprepitant and dexamethasone for prevention of emesis in highly emetic risk ...